Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Zhifei Biological Products Co., Ltd.
  6. News
  7. Summary
    300122   CNE100000V20

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

(300122)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hong Kong stocks end higher as investors bet on vaccine progress

12/03/2020 | 03:31am EDT

Dec 3 (Reuters) - Hong Kong stocks ended marginally higher on Thursday, lifted by hopes for additional U.S. economic stimulus and optimism over a COVID-19 vaccine that could potentially bring the pandemic under control.

** Britain approved Pfizer Inc's COVID-19 vaccine on Wednesday, jumping ahead of the rest of the world in the race to begin the most crucial mass inoculation programme in history.

** Meanwhile, the Institute of Microbiology at the Chinese Academy of Sciences said on Thursday that it worked with China's Chongqing Zhifei to carry out phase III trial of a coronavirus vaccine in Hunan province in November.

** At the close of trade, the Hang Seng index was up 195.92 points or 0.74% at 26,728.50. The Hang Seng China Enterprises index rose 0.12% to 10,586.37. ** The top gainer in the Hang Seng was CSPC Pharmaceutical Group Ltd, which gained 5.91%, while the biggest loser was CITIC Ltd, which fell 6.47%.

** Some investors said the market also looked forward to additional economic stimulus from Washington. Republicans and Democrats in Congress remained unable to reach agreement on fresh relief for a pandemic-hit U.S. economy on Wednesday, however, there were early signs that a $908 billion bipartisan proposal could be gaining traction as a negotiating tool.

** Around the region, MSCI's Asia ex-Japan stock index was firmer by 0.27%, while Japan's Nikkei index closed up 0.03%.

(Reporting by Winni Zhou and Andrew Galbraith, Editing by Sherry Jacob-Phillips)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 1.50% 157.89 End-of-day quote.6.75%
CITIC LIMITED -0.47% 8.4 End-of-day quote.53.01%
CSPC PHARMACEUTICAL GROUP LIMITED -1.87% 10.48 End-of-day quote.32.16%
HANG SENG -1.32% 25935.58 Real-time Quote.-4.76%
NIKKEI 225 -1.80% 27283.59 Real-time Quote.-0.59%
PFIZER, INC. 0.05% 42.81 Delayed Quote.16.30%
All news about CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
07/18CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : Zhifei Biological's COVID-19 Vaccine Reta..
MT
06/28Are Chinese COVID-19 shots effective against the Delta variant?
RE
06/11Chongqing Zhifei Biological Products Co., Ltd. Approves 2020 Profit Distribut..
CI
06/09China to study using CanSinoBIO COVID shots as a booster
RE
05/06Shares of China vaccine makers slump on U.S. waiver support
RE
04/20Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Dividend for th..
CI
04/19Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for t..
CI
04/19CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China trials mixing of CanSinoBIO's and Z..
RE
03/15CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China IMCAS's COVID-19 vaccine obtained e..
RE
02/02Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect..
RE
More news
Financials
Sales 2021 26 005 M 4 025 M 4 025 M
Net income 2021 7 311 M 1 132 M 1 132 M
Net cash 2021 4 294 M 665 M 665 M
P/E ratio 2021 34,9x
Yield 2021 0,69%
Capitalization 253 B 39 096 M 39 100 M
EV / Sales 2021 9,55x
EV / Sales 2022 7,39x
Nbr of Employees 3 380
Free-Float 14,7%
Chart CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Chongqing Zhifei Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 157,89 CNY
Average target price 224,93 CNY
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Ren Sheng Jiang Chairman & General Manager
Zhen Jing Li Chief Financial Officer & Director
Yu Qin Wu Chairman-Supervisory Board
Xin Rong Zhang Independent Director
Bao Kui Liu Independent Director
Sector and Competitors